

Inactivation of the DNA Repair Gene *O*⁶-Methylguanine-DNA Methyltransferase by Promoter Hypermethylation is a Common Event in Primary Human Neoplasia¹

Manel Esteller, Stanley R. Hamilton, Peter C. Burger, Stephen B. Baylin, and James G. Herman²

Tumor Biology, The Johns Hopkins Oncology Center [M. E., S. B. B., J. G. H.], Division of GI-Liver Pathology [S. R. H.], and Department of Pathology [P. C. B.], The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231

Abstract

The DNA repair protein *O*⁶-methylguanine DNA methyltransferase (MGMT) removes alkyl adducts from the *O*⁶ position of guanine. MGMT expression is decreased in some tumor tissues, and lack of activity has been observed in some cell lines. Loss of expression is rarely due to deletion, mutation, or rearrangement of the *MGMT* gene, but methylation of discrete regions of the CpG island of *MGMT* has been associated with the silencing of the gene in cell lines. We used methylation-specific PCR to study the promoter methylation of the *MGMT* gene. All normal tissues and expressing cancer cell lines were unmethylated, whereas nonexpressing cancer cell lines were methylated. Among the more than 500 primary human tumors examined, *MGMT* hypermethylation was present in a subset of specific types of cancer. In gliomas and colorectal carcinomas, aberrant methylation was detected in 40% of the tumors, whereas in non-small cell lung carcinomas, lymphomas, and head and neck carcinomas, this alteration was found in 25% of the tumors. *MGMT* methylation was found rarely or not at all in other tumor types. We also analyzed MGMT expression by immunohistochemistry in relation to the methylation status in 31 primary tumors. The presence of aberrant hypermethylation was associated with loss of MGMT protein, in contrast to retention of protein in the majority of tumors without aberrant hypermethylation. Our results suggest that epigenetic inactivation of *MGMT* plays an important role in primary human neoplasia.

Introduction

MGMT³ is a DNA repair protein that removes mutagenic and cytotoxic adducts from *O*⁶-guanine in DNA (1). Alkylation of DNA at the *O*⁶ position of guanine is an important step in the formation of mutations in cancer, primarily due to the tendency of the *O*⁶-methylguanine to pair with thymine during replication, resulting in a conversion of guanine-cytosine to adenine-thymine pairs in DNA (2). Furthermore, the *O*⁶-alkylguanine-DNA adduct may cross-link with the opposite cytosine residues, blocking DNA replication (3). *MGMT* protect cells against these lesions, transferring the alkyl group from the *O*⁶-guanine in DNA to an active cysteine within its own sequence in a reaction that inactivates one *MGMT* molecule for each lesion repaired (1). Thus, the ability of a cell to withstand such damage is directly related to the number of *MGMT* molecules it contains and to the rate of *de novo* synthesis of *MGMT*.

The amounts of MGMT protein differ according to cellular type (4, 5) and are decreased in some tumors, with respect to their normal tissue counterpart (5, 6). A subset of tumor cell lines, termed Mer-, lack *MGMT* activity (7). Because loss of expression is not commonly due to deletion, mutation or rearrangement of the *MGMT* gene (7-9), or mRNA instability (10), other causes for loss of activity may be involved. Hypermethylation of normally unmethylated CpG islands in the promoter regions of many genes correlates with loss of transcription (11), and the human *MGMT* gene possesses a CpG island (12). Recent work has reported that methylation of discrete regions of the *MGMT* CpG island is associated with the silencing of the gene in cell lines (13-15). To study the relevance of the promoter hypermethylation of the *MGMT* gene *in vivo*, we have examined a series of more than 500 primary human tumors and corresponding normal tissues for *MGMT* aberrant methylation using MSP. Our results indicate that, in certain human cancers, *MGMT* function is lost frequently in association with hypermethylation of the promoter region and that this event may be an important step in human tumorigenesis.

Materials and Methods

MSP. DNA methylation patterns in the CpG island of the *MGMT* gene were determined by chemical modification of unmethylated, but not the methylated, cytosines to uracil and subsequent PCR using primers specific for either methylated or the modified unmethylated DNA (16). Primer sequences of *MGMT* were for the unmethylated reaction 5'-TTTGTGTTTGTATGTTTGTAGGTTTTGT-3' (upper primer) and 5'-AACTCCACACTTCCAA-AAACAAAACA-3' (lower primer) and for the methylated reaction 5'-TTT-CGACGTTTCGTAGGTTTTCGC-3' (upper primer) and 5'-GCACCTTCC-GAAAACGAAACG-3' (lower primer). The annealing temperature was 59°C. Placental DNA treated *in vitro* with Sss I methyltransferase (New England Biolabs) was used as positive control for methylated alleles of *MGMT*, and DNA from normal lymphocytes was used as negative control for methylated alleles of *MGMT*.

Briefly, 1 µg of DNA was denatured by NaOH and modified by sodium bisulfite. DNA samples were then purified using Wizard DNA purification resin (Promega), again treated with NaOH, precipitated with ethanol, and resuspended in water. Controls without DNA were performed for each set of PCRs. Each PCR reaction (10 µl) was directly loaded onto nondenaturing 6% polyacrylamide gels, stained with ethidium bromide, and visualized under UV illumination.

Immunohistochemical Staining for MGMT. Sections of formalin-fixed, paraffin-embedded tissue (6 µm thick) were deparaffinized with xylenes for 30 min and dehydrated by using graded ethanols. Immunoperoxidase staining using diaminobenzidine as chromogen was performed with the TechMate 1000 automatic staining system (Ventana, BioTek Solutions, Tucson, AZ). Commercially available Mouse anti-*MGMT* monoclonal antibody (catalogue N99200; Novus Molecular Inc., San Diego, CA), previously referred to as mT3.1 (17), at 1:100 dilution was used. This antibody has previously been demonstrated to be useful for immunohistochemistry and to correlate with *O*⁶-alkylguanine-DNA alkyltransferase activity (18). Nuclear staining was determined by two authors (S. R. H. and P. C. B.) who did not have knowledge of the molecular analysis of those samples.

Received 9/3/98; accepted 1/4/99.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ Supported in part by NIH Grants CA43318, CA64928, CA62924, and CA54396. M. E. is a recipient of a Spanish Ministerio de Educacion y Cultura Award. J. G. H. is a Valvano Foundation Scholar. S. B. B. and J. G. H. receive research funding and are entitled to sales royalties from ONCOR, which is developing products related to research described in this study. The terms of this arrangement have been reviewed and approved by The Johns Hopkins University in accordance with its conflict of interest policies.

² To whom requests for reprints should be addressed, at Tumor Biology, The Johns Hopkins Oncology Center, 424 North Bond Street, Baltimore, MD 21231. Phone: (410) 955-8506; Fax: (410) 614-9884; E-mail: hermanji@welchlink.welch.jhu.edu.

³ The abbreviations used are: MGMT, *O*⁶-methylguanine-DNA methyltransferase; CNU, chloroethylnitrosourea; Mer, methyl excision repair; MNU, *N*-methyl-*N*-nitrosourea; MSP, methylation-specific PCR; NSCLC, non-small cell lung carcinoma.

Results

MGMT Promoter Hypermethylation. DNA obtained from 524 primary human tumors, cancer cell lines, and normal tissues was subjected to *MGMT* promoter methylation study using MSP. The region chosen for *MGMT* spans the area of greatest CpG density immediately 5' to the transcription start site, in an area previously found to be hypermethylated in Mer- cell lines (14, 15). To determine the specificity of our approach, the colon carcinoma cell lines SW48 and HT29, reported previously as a Mer-deficient (Mer-) line and proficient (Mer+) line (19), respectively, were first studied. The SW48 cell line, which did not express *MGMT*, was fully methylated in this region, whereas the *MGMT*-expressing cell line HT29 was completely unmethylated (Fig. 1B). The *MGMT* promoter methylation status was investigated further in a set of normal human tissues, including brain, colonic mucosa, breast, pancreas, lung, and peripheral blood lymphocytes. Among these normal tissues tested, all were completely unmethylated at the *MGMT* gene (Fig. 1A). Thus, the methylation of *MGMT* identified in cell lines must have originated during tumor progression or in cell culture.

To address the relevance of the promoter hypermethylation of the *MGMT* gene *in vivo*, we examined a large series of primary human tumors for aberrant *MGMT* methylation using MSP. The results for the primary tumors with *MGMT* promoter hypermethylation are summarized in Table 1, and examples are shown in Fig. 1. Hypermethylation of *MGMT* was detected in many tumors. Aberrant *MGMT* hypermethylation was most frequent in primary gliomas and colorectal carcinomas, showing aberrant methylation in ~40% of the cases. Among the gliomas and colorectal carcinomas tested, 54 of 140 (38%) and 14 of 36 (38%), respectively, had *MGMT* promoter hypermethylation. Aberrant methylation of *MGMT* in gliomas was found in similar frequencies across the spectrum of grades: astrocytoma/oligodendroglioma (grade II) had hypermethylation in 8 of 26 (31%),

Table 1 Hypermethylation of *MGMT* promoter in primary tumors

	Primary tumors
Brain tumors	55/166 (33%)
Gliomas	54/140 (38%)
Nongliomas	1/26 (3%)
Colon cancer	14/36 (38%)
Lung cancer	10/41 (24%)
NSCLC	10/34 (29%)
SCLC	0/7
Head and neck carcinoma	6/21 (28%)
Lymphomas	15/61 (25%)
Breast cancer	0/36
Ovarian cancer	0/23
Endometrial cancer	0/17
Leukemias	2/31 (6%)
Pancreatic carcinoma	2/18 (11%)
Melanoma	2/18 (11%)
Renal carcinoma	1/12 (8%)
Bladder carcinoma	2/44 (4%)

anaplastic astrocytoma (grade III) in 10 of 20 (50%), and glioblastoma multiforme (grade IV) in 36 of 87 (41%). In contrast to the subtypes described above, the promoter of *MGMT* was unmethylated in meningiomas (*n* = 25), pilocytic astrocytomas (*n* = 4) and ependymomas (*n* = 3). A single medulloblastoma examined was hypermethylated at *MGMT*. We also examined cell lines of these tumor types and generally found a similar incidence of *MGMT* promoter methylation as seen in primary tumors, with two of four (50%) gliomas and three of seven (40%) colon cancer cell lines having aberrant methylation at the *MGMT* CpG island.

A second group of neoplasms with frequent *MGMT* promoter methylation included lymphomas, NSCLCs, and head and neck carcinomas, where this alteration was found in ~25% of the cases (Table 1). In the non-Hodgkin's lymphomas studied, 15 of 62 (24%) were hypermethylated at *MGMT*. The presence of aberrant promoter methylation was a common feature in aggressive/high-grade lymphomas




Fig. 1. MSP of *MGMT*. PBR32/Msp digest are shown at left as molecular weight markers. The presence of a visible PCR product in Lane U indicates the presence of unmethylated genes of *MGMT*; the presence of product in Lane M indicates the presence of methylated genes. A, normal tissues. Corresponding Lanes are: normal brain, colonic mucosa, lung, lymphocytes, liver, kidney, and breast; *in vitro* methylated DNA (IVD) as positive control for methylation; and water control for PCR. B, MSP of *MGMT* in cancer cell lines. Corresponding Lanes are: colon carcinoma cell lines HT-29 (Mer+), SW48 (Mer-), and LoVo (Mer+); *in vitro* methylated DNA as positive control for methylation; and water control for PCR. C, MSP of *MGMT* in primary gliomas. Corresponding Lanes are: primary gliomas (1-5), normal brain (NBrain), SW48 colon cancer cell line as positive control for methylation, normal lymphocytes as negative control for methylation, and water control for PCR reaction. D, MSP of *MGMT* in primary colorectal carcinomas. Corresponding Lanes are: primary colorectal carcinomas (1-6), SW48 as positive control for methylation, normal lymphocytes as negative control for methylation, and water control for PCR reaction. E, MSP of *MGMT* in primary lung carcinomas. Corresponding Lanes are: primary lung carcinomas (1-6), SW48 as positive control for methylation, normal lymphocytes as negative control for methylation, and water control for PCR reaction. F, MSP of *MGMT* in primary lymphomas. Corresponding Lanes are primary lymphomas (1-6).

Table 2 Association of MGMT promoter hypermethylation and loss of MGMT expression in human primary tumors

	Total	Hypermethylated	Unmethylated
All types (<i>n</i> = 31)			
Expressing tumors	18	1	17
Tumors with loss of expression	13	12	1
By types			
Brain tumors (<i>n</i> = 8)			
Expressing tumors	5		5
Tumors with loss of expression	3	3	
Lymphomas (<i>n</i> = 14)			
Expressing tumors	7		7
Tumors with loss of expression	7	6	1
Colorectal carcinomas (<i>n</i> = 9)			
Expressing tumors	6	1	5
Tumors with loss of expression	3	3	

where 11 of 14 (79%) were hypermethylated, including all 9 diffuse large cell lymphomas analyzed. In contrast, this *MGMT* epigenetic alteration was uncommon in indolent/low-grade lymphomas, where only 2 of 22 (9%) cases had *MGMT* methylation.

Hypermethylation of the *MGMT* promoter was not a universal finding in cancers in general, however. In contrast to the tumor types described above, other tumor types had infrequent *MGMT* promoter methylation: 2 of 18 (11%) pancreatic carcinomas, 2 of 18 (11%) melanomas, 1 of 12 (8%) renal carcinomas, 2 of 31 (6%) acute leukemias (1 AML and 1 ALL), and 2 of 44 (4%) bladder carcinomas. Finally, no carcinomas of the breast (*n* = 36), endometrium (*n* = 17), ovary (*n* = 23), or SCLCs (*n* = 7) analyzed had aberrant *MGMT* methylation.

In primary tumors, unlike cancer cell lines that were often either completely methylated or completely unmethylated in this region of the *MGMT* CpG island (Fig. 1B), hypermethylation of *MGMT* was always accompanied by amplification in the unmethylated reaction as well. The presence of this unmethylated *MGMT* region could indicate the presence of normal tissues in these nonmicrodissected samples, with unmethylated *MGMT* alleles, as observed in Fig. 1A. However, heterogeneity in the patterns of methylation in the tumor itself might also be present. To address this issue, we sought to determine the consequences of hypermethylation of the CpG island of *MGMT* on expression of this enzyme.

Expression of MGMT in Primary Tumors. Levels of *MGMT* expression often vary in primary tumors (5, 6). *MGMT* activity in primary tumors may be affected by contamination of tumor tissue with normal cells, such as endothelial cells, reactive astrocytes, or infiltrating lymphocytes, which express *MGMT*. Previous studies comparing *MGMT* activity, Western blot analysis, and immunohistochemistry have demonstrated only a moderate association between these methods of determining *MGMT* expression in colon carcinoma and normal colon (20). For these reasons, we analyzed *MGMT* expression by immunohistochemistry so that the expression in the neoplastic cells could be directly measured, using a previously characterized antibody (18). We first examined cell lines with known *MGMT* expression and methylation patterns to validate this approach. Expression of *MGMT* was absent in SW48 (Mer- and hypermethylated at the *MGMT* promoter), but was present in the Mer+ colon cancer cell lines HT29 and LoVo (data not shown).

Paraffin sections from 31 human primary tumors (including 8 brain tumors, 9 colon carcinomas, and 14 lymphomas) were then studied for *MGMT* expression. The immunohistochemical data related to *MGMT* promoter hypermethylation are shown in Table 2, and examples of the results obtained are shown in Fig. 2. All sections examined had nuclear staining of *MGMT* in normal cells adjacent to or within tumors, although in some cases this staining was weak. This provided an internal positive control. Among the 31 total tumors analyzed, 13

were judged to have loss of *MGMT* expression, whereas 18 tumors expressed *MGMT*. The level of expression observed in tumors varied greatly, and tumors that expressed *MGMT* often demonstrated higher expression than adjacent normal tissue. In the majority of these high *MGMT* expressing tumors, the expression was homogeneously increased. However, some cell to cell variation within in the neoplastic cells was observed. This finding is consistent with previous studies in these and other tissue types that tumor formation may be associated with increased levels of *MGMT* (20–23). However, a subset of tumors had diminished or absent *MGMT* expression, and in these tumors, protein was absent in the majority of tumor cells, with only occasional cells expressing detectable *MGMT* protein. The loss of staining was most uniform in the lymphomas, with greater cellular heterogeneity in the colon and brain tumors. Similar heterogeneity has been reported in colon (20) and lung (23) carcinomas demonstrating decreased expression of *MGMT* measured by immunohistochemistry.

When the expression data were matched to previous studies of the methylation of *MGMT*, 12 of 13 tumors that lack *MGMT* expression (92%) showed *MGMT* promoter hypermethylation, whereas 17 of 18 (94%) tumors that retained expression of *MGMT* were unmethylated at the *MGMT* CpG island (Fisher's exact test, <0.0001). This association between loss of *MGMT* expression and promoter hypermethylation was seen in each of the tumor types examined (Table 2). Among eight gliomas (five glioblastomas multiforme, two anaplastic astrocytomas, and one pilocytic astrocytoma), three had loss of protein expression and *MGMT* promoter hypermethylation, whereas five retained *MGMT* expression and were unmethylated at *MGMT*. Among nine primary colorectal carcinomas, three had lack of *MGMT* expression associated with abnormal *MGMT* methylation, whereas six of seven (85%) expressing tumors were unmethylated at *MGMT*. In all cases, adjacent normal colon epithelia expressed the *MGMT* protein. In two colonic carcinoma cases, we were able to examine *MGMT* expression in both primary and metastatic lesions. A hepatic metastasis from a primary tumor hypermethylated at *MGMT*, which lacked expression of the protein, also demonstrated loss of *MGMT* expression, whereas a lymph node metastasis from an unmethylated primary tumor, which expressed *MGMT*, retained *MGMT* expression in the metastasis. Finally, the analysis of 14 lymphomas (8 diffuse lymphomas, 5 follicular lymphomas, and 1 marginal zone lymphoma) revealed that among seven tumors showing loss of *MGMT* expression, six had *MGMT* promoter methylation, whereas all seven expressing tumors were unmethylated at the *MGMT* loci.

Discussion

In cell culture, a causal relationship between methylation of the *MGMT* CpG island and transcriptional silencing of the gene has been demonstrated (13–15). Our data now demonstrate that *MGMT* promoter hypermethylation associated with loss of expression is frequent in primary human neoplasia as well. The tight correlation between *MGMT* CpG island methylation and loss of expression in these tumors provides an explanation for the loss of *MGMT* activity previously reported in a subset of many tumor types (5, 6, 20, 21, 23, 24). However, in tumor types where we did not detect *MGMT* hypermethylation, such as breast, ovarian carcinoma, or meningioma, decreased *MGMT* activity is infrequent (5, 6, 24).

Because *MGMT* plays a major role in the repair of the *O*⁶-methylguanine DNA adducts, which are formed after exposure to methylating agents [including the monofunctional alkylating agents MNU or MNNG (*N*-methyl-*N'*-nitro-*N*-nitrosoguanidine)] and to clinical drugs such as dacarbazine, procarbazine, temozolomide, lomustine [CCNU, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea], nimustine [ACNU, 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chlo-




Fig. 2. Immunohistochemistry of *MGMT* gene product in primary human tumors. *A*, anaplastic astrocytoma unmethylated at *MGMT* showing expression of the protein in tumor cell nuclei. *B*, glioblastoma multiforme with *MGMT* promoter hypermethylation lacking expression in the majority of malignant cells. *C*, colonic carcinoma unmethylated at *MGMT* expressing the protein, whereas another colonic carcinoma in *D* with aberrant methylation at *MGMT* shows complete lack of expression in tumor nuclei, but expression in stromal cells. *E*, follicular lymphoma unmethylated at *MGMT* promoter showing expression of the protein. *F*, diffuse lymphoma hypermethylated at *MGMT* demonstrating loss of *MGMT* expression.

roethyl)-3-nitrosourea], and carmustine [BCNU, 1,3-bis(2-chloroethyl)-1-nitrosourea], our results identify potentially critical events in carcinogenesis and may define a set of chemosensitive tumors. During DNA replication, *O*⁶-methylguanine can pair with thymine, resulting in conversion of guanine-cytosine to adenine-thymine pairs in DNA (2). Such mutations are often present in tumors induced by alkylating agents (25). To counteract these effects, *MGMT* protein can remove such adducts before mutations result. Thus, *MGMT* gene knockout mice have a higher suscepti-

bility to MNU-induced tumorigenesis, specifically manifesting more frequent lung adenomas and thymic lymphomas when compared with wild-type mice (26). Our findings that primary NSCLCs and lymphomas are tumor types with frequent methylation-associated inactivation of the *MGMT* gene suggest that this epigenetic alteration may confer an increased risk of alkylating agent-induced carcinogenesis in the systems of these organs.

The importance of *MGMT* in carcinogenesis is also evident in the *MGMT* transgenic mice, who possess protection against skin carcino-

genesis, thymic lymphomas, and aberrant crypt foci of the colon induced by alkylating agents (27–29). Interestingly, simple methylating agents, such as MNU, ACNU (a CNU derivative), and NNK [4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone], a nitrosamine present in tobacco and tobacco smoke, have been shown to induce *ras* mutations (30–32). Tumor types with silencing of the *MGMT* by aberrant promoter hypermethylation in this study include those that have a frequent rate of *K-ras* mutations described in the literature, such as colon, lung, and head and neck carcinomas (30). This suggests that one potential consequence of loss of *MGMT* expression could be an increase in susceptibility to *K-ras* mutation. The *MGMT* transgenic mouse, in fact, is not only protected against aberrant crypt foci formation, but also has a lower incidence of crypt foci with G to A mutations in *K-ras* (29). However, other tumors associated with carcinogen exposure, such as bladder carcinoma, and other tumors with a high rate of *K-ras* mutations, such as pancreatic carcinoma, were not frequent targets of *MGMT* promoter hypermethylation, suggesting that inactivation of *MGMT* is not required for the acquisition of *K-ras* mutations.

From a clinical standpoint, *MGMT* promoter hypermethylation with subsequent loss of *MGMT* expression might play a role in modulating chemosensitivity to alkylating agents. CNU and methylating agents, such as streptozotocin, are commonly used in the treatment of neoplastic diseases such as brain tumors, colon carcinoma, malignant melanoma, Hodgkin's disease, lymphoma, myeloma, and skin cancer. Among the tumors studied in the present study, gliomas, colon carcinomas, and lymphomas had the highest frequency of *MGMT* promoter hypermethylation. These tumor types, in addition to NSCLC, have all been reported to have decreased *MGMT* expression and activity (5, 6, 20, 21, 23, 24, 33) in a subset of tumors. Thus, the decreased *MGMT* activity observed in a significant fraction of these tumors and the response of the former tumor types to CNU may be due, in part, to the lack of *O*⁶-chloroethylguanine repair by inactivation at *MGMT* by aberrant promoter methylation. The tight correlation between loss of expression at the protein level and hypermethylation of the *MGMT* 5' CpG island we report in our study directly links these two processes *in vivo* and suggests an important role for aberrant promoter hypermethylation of *MGMT* in primary human cancer.

Acknowledgments

We acknowledge numerous colleagues who provided primary tumor samples and cell lines for this study, most notably Dr. Adrian Merlo. We also thank Dr. Anthony Pegg for helpful discussion.

References

- Pegg, A. E. Mammalian *O*⁶-alkylguanine-DNA alkyltransferase regulation and importance in response to alkylating carcinogenic and therapeutic agents. *Cancer Res.*, 50: 6119–6129, 1990.
- Coulondre, C., and Miller, J. H. Genetic studies of the lac repressor IV. Mutagenic specificity in the *lacI* gene of *Escherichia coli*. *J. Mol. Biol.*, 117: 577–606, 1977.
- Erickson, L. C., Laurent, G., Sharkey, N. A., and Kohn, K. W. DNA cross-linking and monoadduct repair in nitrosourea-treated human tumour cells. *Nature (Lond.)*, 288: 727–729, 1980.
- Gerson, S. L., Trey, J. E., Miller, K., and Berger, N. A. Comparison of *O*⁶-alkylguanine-DNA-alkyltransferase activity based on cellular DNA content in human, rat and mouse tissues. *Carcinogenesis (Lond.)*, 7: 745–749, 1986.
- Citron, M. R., Decker, S., Chen, S., Schneider, M., Graver, L., Kleynerman, L. B., Kahn, A., White, M., Schoenhaus, M., and Yarosh, D. *O*⁶-methylguanine-DNA methyltransferase in human normal and tumor tissue from brain, lung, and ovary. *Cancer Res.*, 51: 4131–4134, 1991.
- Citron, M., Graver, M., Schoenhaus, M., Chen, S., Decker, R., Kleynerman, L., Kahn, L. B., White, A., Fornace, A. J., and Yarosh, D. Detection of messenger RNA from *O*⁶-methylguanine-DNA methyltransferase gene *MGMT* in human normal and tumor tissues. *J. Natl. Cancer Inst.*, 84: 337–340, 1992.
- Day, R. S., III, Ziolkowski, C. H., Scudiero, D. A., Meyer, S. A., Lubiniecki, A. S., Girardi, A. J., Galloway, S. M., and Bynum, G. D. Defective repair of alkylated DNA by human tumor and SV40-transformed human cell strains. *Nature (Lond.)*, 288: 724–727, 1980.
- Fornace, A. J., Jr., Papathanasiou, M. A., Hollander, M. C., and Yarosh, D. B. Expression of the *O*⁶-methylguanine DNA methyltransferase gene *MGMT* in MER+ and MER- human tumor cells. *Cancer Res.*, 50: 7908–7911, 1990.
- Pieper, R. O., Futscher, B. W., Dong, Q., Ellis, T. M., and Erickson, L. C. Comparison of *O*⁶-methylguanine-DNA methyltransferase gene (*MGMT*) mRNA levels in MER+ and MER- human tumor cell lines containing the *MGMT* gene by the polymerase chain reaction technique. *Cancer Commun.*, 2: 13–20, 1990.
- Kroes, R. A., and Erickson, L. C. The role of mRNA stability and transcription in *O*⁶-methylguanine-DNA methyltransferase (*MGMT*) expression in Mer- human tumor cell lines. *Carcinogenesis (Lond.)*, 16: 2255–2257, 1995.
- Baylin, S. B., Herman, J. G., Graff, J. R., Vertino, P. M., and Issa, J. P. Alterations in DNA methylation: a fundamental aspect of neoplasia. *Adv. Cancer Res.*, 72: 141–196, 1998.
- Harris, L. C., Potter, P. M., Tano, K., Shiota, S., Mitra, S., and Brent, T. P. Characterization of the promoter region of the human *O*⁶-methylguanine-DNA methyltransferase gene. *Nucleic Acids Res.*, 19: 6163–6167, 1991.
- Costello, J. F., Futscher, B. W., Tano, K., Graunke, D. M., and Pieper, R. O. Graded methylation in the promoter and in the body of the *O*⁶-methylguanine-DNA methyltransferase gene correlates with *MGMT* expression in human glioma cells. *Cancer Res.*, 56: 13916–13924, 1996.
- Qian, X. C., and Brent, T. P. Methylation hot spots in the 5'-flanking region denote silencing of the *O*⁶-Methylguanine-DNA methyltransferase gene. *Cancer Res.*, 57: 3672–3677, 1997.
- Watts, G. S., Pieper, R. O., Costello, J. F., Peng, Y.-M., Dalton, W. S., and Futscher, B. W. Methylation of discrete regions of the *O*⁶-Methylguanine DNA methyltransferase (*MGMT*) CpG island is associated with heterochromatinization of the *MGMT* transcription start site and silencing of the gene. *Mol. Cell. Biol.*, 17: 5612–5619, 1997.
- Herman, J. G., Graff, J. R., Myohanen, S., Nelkin, B. D., and Baylin, S. B. Methylation-specific PCR. A novel PCR assay for methylation status of CpG islands. *Proc. Natl. Acad. Sci. USA*, 93: 9821–9826, 1996.
- Brent, T. P., von Wronski, M., Pegram, C. N., and Bigner, D. D. Immunoaffinity purification of human *O*⁶-alkylguanine-DNA alkyltransferase using newly developed monoclonal antibodies. *Cancer Res.*, 50: 58–61, 1990.
- Reese, J. S., Koc, O. N., Lee, K. M., Liu, L., Allay, J. A., Phillips, W. P., Jr., and Gerson, S. L. Retroviral transduction of a mutant methylguanine DNA methyltransferase gene into human CD34 cells confers resistance to *O*⁶-benzylguanine plus 1,3-bis(2-chloroethyl)-1-nitrosourea. *Proc. Natl. Acad. Sci. USA*, 93: 14088–14093, 1996.
- Branch, P., Hampson, R., and Karran, P. DNA mismatch binding defects, DNA damage tolerance, and mutator phenotypes in human colorectal carcinoma cell lines. *Cancer Res.*, 55: 2304–2309, 1995.
- Zaidi, N. H., Liu, L., and Gerson, S. L. Quantitative immunohistochemical estimates of *O*⁶-alkylguanine-DNA alkyltransferase expression in normal and malignant human colon. *Clin. Cancer Res.*, 2: 577–584, 1996.
- Silber, J. R., Bobola, M. S., Ghatan, S., Blank, A., Kolstoe, D. D., and Berger, M. S. *O*⁶-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics. *Cancer Res.*, 58: 1068–1073, 1998.
- Kokkinakis, D. M., Ahmed, M. M., Delgado, R., Fruitwala, M. M., Mohiuddin, M., and Albores-Saavedra, J. Role of *O*⁶-methylguanine-DNA methyltransferase in the resistance of pancreatic tumors to DNA alkylating agents. *Cancer Res.*, 57: 5360–5368, 1997.
- Mattern, J., Koomagi, R., and Volm, M. Smoking-related increase of *O*⁶-methylguanine-DNA methyltransferase expression in human lung carcinomas. *Carcinogenesis (Lond.)*, 19: 1247–1250, 1998.
- Mineura, K., Izumi, I., Watanabe, D., and Kowada, M. *O*⁶-alkylguanine-DNA alkyltransferase activity in human brain tumors. *Tohoku J. Exp. Med.*, 165: 223–228, 1991.
- Sukumar, S., Notario, V., Martin-Zanca, D., and Barbacid, M. Induction of mammary carcinomas in rats by nitroso-methylurea involves malignant activation of *H-ras-1* locus by single point mutations. *Nature (Lond.)*, 306: 658–661, 1983.
- Sakumi, K., Shiraishi, A., Shimizu, S., Tsuzuki, T., Ishikawa, T., and Sekiguchi, M. Methylnitrosourea-induced tumorigenesis in *MGMT* gene knockout mice. *Cancer Res.*, 57: 2415–2418, 1997.
- Dumenco, L. L., Allay, E., Norton, K., and Gerson, S. L. The prevention of thymic lymphomas in transgenic mice by human *O*⁶-alkylguanine-DNA alkyltransferase. *Science (Washington DC)*, 259: 219–222, 1993.
- Becker, K., Dosch, J., Gregel, C. M., Martin, B. A., and Kaina, B. Targeted expression of human *O*⁶-methylguanine-DNA methyltransferase (*MGMT*) in transgenic mice protects against tumor initiation in two-stage skin carcinogenesis. *Cancer Res.*, 56: 3244–3249, 1996.
- Zaidi, N. H., Pretlow, T. P., O'Riordan, M. A., Dumenco, L. L., Allay, E., and Gerson, S. L. Transgenic expression of human *MGMT* protects against azoxymethane-induced aberrant crypt foci and G to A mutations in the *K-ras* oncogene of mouse colon. *Carcinogenesis (Lond.)*, 16: 451–456, 1995.
- Barbacid, M. *ras* genes. *Annu. Rev. Biochem.*, 56: 779–827, 1987.
- Belinsky, S. A., Devereux, T. R., Maronpot, R. R., Stoner, G. D., and Anderson, M. W. Relationship between the formation of promutagenic adducts and the activation of the *K-ras* protooncogene in lung tumors from A/J mice treated with nitrosamines. *Cancer Res.*, 49: 5305–5311, 1989.
- Inga, A., Iannone, R., Campomenosi, P., Molina, F., Menichini, P., Abbondandolo, A., and Fronza, G. Mutational fingerprint induced by the antineoplastic drug chloroethylcyclohexyl-nitrosourea in mammalian cells. *Cancer Res.*, 55: 4658–4663, 1995.
- Chen, J., Zhang, Y.-P., Wang, C., Sun, Y., Fujimoto, J., and Ikenaga, M. *O*⁶-Methylguanine-DNA methyltransferase activity in human tumors. *Carcinogenesis (Lond.)*, 13: 1503–1507, 1992.

Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

Inactivation of the DNA Repair Gene *O⁶-Methylguanine-DNA Methyltransferase* by Promoter Hypermethylation is a Common Event in Primary Human Neoplasia

Manel Esteller, Stanley R. Hamilton, Peter C. Burger, et al.

Cancer Res 1999;59:793-797.

Updated version Access the most recent version of this article at:
<http://cancerres.aacrjournals.org/content/59/4/793>

Cited articles This article cites 33 articles, 17 of which you can access for free at:
<http://cancerres.aacrjournals.org/content/59/4/793.full#ref-list-1>

Citing articles This article has been cited by 100 HighWire-hosted articles. Access the articles at:
<http://cancerres.aacrjournals.org/content/59/4/793.full#related-urls>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cancerres.aacrjournals.org/content/59/4/793>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.